Filter

41 - 50 of 517 Results

  • The Facts About the $35 Insulin Copay Cap in Medicare

    Policy Watch

    This brief describes the facts about actions taken under both the Trump and Biden Administrations related to capping insulin copayments for people with Medicare and explains the differences between their approaches.

  • Medicare 101

    Feature

    This Health Policy 101 chapter explores Medicare, a federal health insurance program covering more than 66 million people, established in 1965 for people age 65 or older and later expanded to cover people under age 65 with long-term disabilities. In addition to detailing Medicare eligibility, coverage, and spending, the chapter examines the increased role of private plans in providing benefits and the financing challenges posed by increasing health care costs and an aging population.

  • How Many Older Adults Live in Poverty?

    Issue Brief

    To provide context for understanding the financial needs and well-being of older adults, this brief analyzes the latest data on poverty rates among the 58 million non-institutionalized adults ages 65 and older in the U.S overall, based on both the official poverty measure and the Supplemental Poverty Measure.

  • A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity

    Issue Brief

    The FDA recently approved a new use for Wegovy, the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese - a decision that opens the door to Medicare coverage of Wegovy, which is prohibited by law from covering drugs used for obesity. This brief analyses how many Medicare beneficiaries could be eligible for the new use of Wegovy and the potential impact on Medicare spending.

  • FAQs on Prescription Drug Importation

    Issue Brief

    These FAQs address questions related to prescription drug importation, including the current status of importation proposals, details of Florida’s importation program recently authorized by the FDA, and concerns and challenges with this approach.